MacroGenics, Inc.
(NASDAQ : MGNX)

( )
MGNX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.90%168.391.3%$496.78m
BIIBBiogen Inc.
0.65%230.761.3%$480.84m
CELGCelgene Corporation
-0.62%94.831.3%$471.13m
GILDGilead Sciences, Inc.
-0.75%65.860.9%$453.88m
ILMNIllumina, Inc.
-2.29%300.593.5%$305.96m
REGNRegeneron Pharmaceuticals, Inc.
-0.78%302.572.6%$276.84m
AAgilent Technologies, Inc.
-0.29%68.911.6%$198.64m
VRTXVertex Pharmaceuticals Incorporated
-1.78%165.731.9%$176.80m
EXASExact Sciences Corporation
-0.16%96.0425.3%$171.72m
ALXNAlexion Pharmaceuticals, Inc.
-2.80%127.232.0%$150.06m
BMRNBioMarin Pharmaceutical Inc.
-2.31%86.664.3%$118.53m
SRPTSarepta Therapeutics, Inc.
-3.37%117.5714.7%$114.20m
INCYIncyte Corporation
-0.48%76.832.5%$105.26m
IONSIonis Pharmaceuticals, Inc.
0.09%67.468.2%$98.12m
ALNYAlnylam Pharmaceuticals, Inc
-2.49%65.869.2%$93.34m

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.